
The Breast Friends Podcast Ep. 2 | The 2026 Breast Oncology Forecast
Episode 2
What’s coming in 2026 is about to reshape breast oncology. In Episode 2, Dr. Jason Mouabbi and Dr. Paolo Tarantino go beyond published data to tackle the tough questions about what's next. They break down the evolving landscape of KEYNOTE-756, the rise of oral SERDs in the first line, and the role of HER2DX. From T-DXd in early disease and CNS risk in HER2+, to the promise of improving outcomes in triple-negative breast cancer, they are laying out the roadmap for the future of care. The landscape is moving fast. Listen in as we prepare for the next wave of practice-changing data. ▶️ Watch on YouTube - https://youtu.be/Skt3jGMBncM 🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, & Amazon Music #BreastCancer #Oncology #OncologyPodcast #ClinicalTrials #CancerResearch #HER2Positive #TripleNegative #OralSERD #ADCs #MedicalOncology #MedEd #CancerCare
Publisher
The Breast Friends Podcast
Link
podcasters.spotify.com/pod/show/thebreastfriendspodcast/episodes/The-Breast-Friends-Podcast-Ep--2--The-2026-Breast-Oncology-Forecast-e3f4dqg
Published
February 17, 2026
Duration
52 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Host
Dr. Jason Mouabbi and Dr. Paolo Tarantino
The Breast Friends Podcast
@thebreastfriendspodcast
#breastoncologyforecast #medicine
